EX-8 2 d748399dex8.htm EX-8 EX-8

Exhibit 8

Dr. Reddy’s Laboratories Limited

Subsidiary companies

As of March 31, 2014

 

Name of the subsidiary

   Country of
Incorporation
   Percentage of
Direct/Indirect
Ownership Interest
 

Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.

   Malaysia      100 %(3) 

Aurigene Discovery Technologies Inc.

   U.S.A.      100 %(3) 

Aurigene Discovery Technologies Limited

   India      100

beta Institut gemeinnützige GmbH

   Germany      100 %(8) 

betapharm Arzneimittel GmbH

   Germany      100 %(8) 

Cheminor Investments Limited

   India      100

Chienna BV (from February 15, 2013)

   Netherlands      100 %(14) 

Chirotech Technology Limited

   United Kingdom      100 %(5) 

DRANU LLC (from July 9, 2012)

   U.S.A.      50 %(16) 

Dr. Reddy’s Bio-Sciences Limited

   India      100

Dr. Reddy’s Farmaceutica Do Brasil Ltda.

   Brazil      100

Dr. Reddy’s Laboratories (Australia) Pty. Limited

   Australia      100 %(10) 

Dr. Reddy’s Laboratories Canada, Inc. (from August 29, 2013)

   Canada      100 %(10) 

Dr. Reddy’s Laboratories (EU) Limited

   United Kingdom      100 %(10) 

Dr. Reddy’s Laboratories Inc.

   U.S.A.      100 %(10) 

Dr. Reddy’s Laboratories International SA

   Switzerland      100 %(10) 

Dr. Reddy’s Laboratories, LLC Ukraine

   Ukraine      100 %(10) 

Dr. Reddy’s Laboratories Louisiana LLC

   U.S.A.      100 %(6) 

Dr. Reddy’s Laboratories New York, Inc.

   U.S.A.      100 %(10) 

Dr. Reddy’s Laboratories (Proprietary) Limited

   South Africa      100 %(10) 

Dr. Reddy’s Laboratories Romania S.R.L.

   Romania      100 %(10) 

Dr. Reddy’s Laboratories SA

   Switzerland      100

Dr. Reddy’s Laboratories Tennessee, LLC

   U.S.A.      100 %(6) 

Dr. Reddy’s Laboratories (UK) Limited

   United Kingdom      100 %(5) 

Dr. Reddy’s New Zealand Limited.

   New Zealand      100 %(10) 

Dr. Reddy’s Pharma SEZ Limited

   India      100

Dr. Reddy’s Singapore PTE Limited, Singapore (from October 22, 2013)

   Singapore      100 %(10) 

Dr. Reddy’s Srl

   Italy      100 %(11) 

Dr. Reddy’s Venezuela, C.A.

   Venezuela      100 %(10) 

DRL Impex Limited

   India      100

Eurobridge Consulting B.V.

   Netherlands      100 %(1) 

Industrias Quimicas Falcon de Mexico, S.A. de CV

   Mexico      100

Idea2Enterprises (India) Pvt. Limited

   India      100

I-Ven Pharma Capital Limited

   India      100 %(2)(12) 

Kunshan Rotam Reddy Pharmaceutical Co. Limited (JV)

   China      51.33 %(4) 

Lacock Holdings Limited

   Cyprus      100 %(10) 

OOO Dr. Reddy’s Laboratories Limited

   Russia      100 %(10) 

OOO DRS LLC

   Russia      100 %(9) 

OctoPlus N.V. (from February 15, 2013)

   Netherlands      100 %(13) 

OctoPlus Development B.V. (from February 15, 2013)

   Netherlands      100 %(14) 

OctoPlus Sciences B.V. (from February 15, 2013)

   Netherlands      100 %(14) 

OctoPlus PolyActive Sciences B.V. (from February 15, 2013)

   Netherlands      100 %(15) 

OctoPlus Technologies B.V. (from February 15, 2013)

   Netherlands      100 %(14) 

OctoShare B.V. (from February 15, 2013)

   Netherlands      100 %(14) 

Promius Pharma LLC

   U.S.A.      100 %(6) 

Reddy Antilles N.V.

   Netherlands      100

Reddy Specialities GmbH (formerly Reddy beta GmbH)

   Germany      100 %(8) 

Reddy Cheminor S.A.

   France      100 %(2) 

Reddy Holding GmbH

   Germany      100 %(10) 

Reddy Netherlands B.V.

   Netherlands      100 %(10) 

Reddy Pharma Iberia SA

   Spain      100

Reddy Pharma Italia S.p.A.

   Italy      100 %(7) 

Reddy US Therapeutics Inc. (until July 3, 2013)

   U.S.A.      100 %(1) 

 


(1)

Indirectly owned through Reddy Antilles N.V.

(2)

Subsidiary under liquidation.

(3)

Indirectly owned through Aurigene Discovery Technologies Limited.

(4)

Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary, as we hold a 51.33% stake. However, we account for this investment by the equity method and do not consolidate it in our financial statements.

(5)

Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.

(6)

Indirectly owned through Dr. Reddy’s Laboratories Inc.

(7)

Indirectly owned through Lacock Holdings Limited.

(8)

Indirectly owned through Reddy Holding GmbH.

(9)

Indirectly owned through Eurobridge Consulting B.V.

(10)

Indirectly owned through Dr. Reddy’s Laboratories SA.

(11)

Indirectly owned through Reddy Pharma Italia S.p.A.

(12)

Indirectly owned through DRL Impex Limited

(13)

Indirectly owned through Reddy Netherlands B.V.

(14)

Indirectly owned through OctoPlus N.V.

(15)

Indirectly owned through OctoPlus Sciences B.V.

(16)

DRANU LLC is consolidated in accordance with guidance available in IFRS 10.